Rimonabant
Sources
registry, as of 2016-05-20Stale
https://clinicaltrials.gov/study/NCT00263042
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes. Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 18695. Conditions Cardiovascular Disease. The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors. The secondary objective is to show whether rimonabant reduces the ri
ClinicalTrials.gov NCT00263042 protocol and results modules
registry, as of 2009-04-20Stale
https://clinicaltrials.gov/study/NCT00029861
Obese Patients With or Without Comorbidities (RIO-North America). Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 3045. Conditions Obesity; Weight Loss. To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities
ClinicalTrials.gov NCT00029861 protocol and results modules
registry, as of 2011-01-26Stale
https://clinicaltrials.gov/study/NCT00405808
Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose. Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 2666. Conditions Obesity. Primary objective: To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese pati
ClinicalTrials.gov NCT00405808 protocol and results modules
registry, as of 2009-04-20Stale
https://clinicaltrials.gov/study/NCT00386061
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe). Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 1507. Conditions Obesity. The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities. The main secondary objectives were to assess the effect of SR141716
ClinicalTrials.gov NCT00386061 protocol and results modules
registry, as of 2009-04-20Stale
https://clinicaltrials.gov/study/NCT00029848
Obese Patients With Type 2 Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 1045. Conditions Obesity; Diabetes Mellitus, Non-Insulin-Dependent; Obesity in Diabetes. To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with Type 2 Diabetes
ClinicalTrials.gov NCT00029848 protocol and results modules
registry, as of 2009-04-20Stale
https://clinicaltrials.gov/study/NCT00029835
Obese Patients With Untreated Dyslipidemias. Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 1033. Conditions Obesity; Dyslipidemia. To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with untreated dyslipidemia
ClinicalTrials.gov NCT00029835 protocol and results modules
registry, as of 2009-07-20Stale
https://clinicaltrials.gov/study/NCT00434096
Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS). Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 915. Conditions Obesity. The primary objective of this study is to assess the efficacy of SR141716 compared to placebo on body weight and triglycerides changes over a period of 52 weeks. Secondary objectives are: * To evaluate the effect of SR141716 compared to placebo over a period of 52 weeks, on HDL
ClinicalTrials.gov NCT00434096 protocol and results modules
registry, as of 2009-04-20Stale
https://clinicaltrials.gov/study/NCT00124332
STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study). Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 839. Conditions Coronary Atherosclerosis. The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered on top of standard behavioral and pharmacological th
ClinicalTrials.gov NCT00124332 protocol and results modules
registry, as of 2009-04-07Stale
https://clinicaltrials.gov/study/NCT00239967
An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients. Overall status COMPLETED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 803. Conditions Dyslipidemia; Obesity. The purpose of this study is to assess the effect of rimonabant 20 mg on HDL (high density lipoprotein) cholesterol and on TG (triglycerides) plasma levels over a period of one year when prescribed with a hypocaloric diet (600 kcal deficit per day) in abdominally obese patients w
ClinicalTrials.gov NCT00239967 protocol and results modules
registry, as of 2016-05-20Stale
https://clinicaltrials.gov/study/NCT00228176
Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant. Overall status TERMINATED. Phases PHASE3. Lead sponsor Sanofi. Enrollment 661. Conditions Carotid Artery Plaque; Arteriosclerosis; Obesity; Metabolic Syndrome X. Objectives: * Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT) * Secondary: To evaluate the safety and tolerability of the abo
ClinicalTrials.gov NCT00228176 protocol and results modules
publication, as of 2005-05-27Stale
https://pubmed.ncbi.nlm.nih.gov/15755787/
antagonist. To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of rimonabant, a new selective cannabinoid receptor antagonist. Primary literature and review articles were obtained via a MEDLINE search (1966-November 2004) using the key terms obesity, smoking cessation, cannabinoid, rimonabant, SR 141716,
PMID 15755787